Literature DB >> 25561683

Safety and feasibility for pediatric cardiac regeneration using epicardial delivery of autologous umbilical cord blood-derived mononuclear cells established in a porcine model system.

Susana Cantero Peral1, Harold M Burkhart1, Saji Oommen1, Satsuki Yamada1, Scott L Nyberg1, Xing Li1, Patrick W O'Leary1, Andre Terzic1, Bryan C Cannon1, Timothy J Nelson2.   

Abstract

Congenital heart diseases (CHDs) requiring surgical palliation mandate new treatment strategies to optimize long-term outcomes. Despite the mounting evidence of cardiac regeneration, there are no long-term safety studies of autologous cell-based transplantation in the pediatric setting. We aimed to establish a porcine pipeline to evaluate the feasibility and long-term safety of autologous umbilical cord blood mononuclear cells (UCB-MNCs) transplanted into the right ventricle (RV) of juvenile porcine hearts. Piglets were born by caesarean section to enable UCB collection. Upon meeting release criteria, 12 animals were randomized in a double-blinded fashion prior to surgical delivery of test article (n=6) or placebo (n=6). The UCB-MNC (3×10(6) cells per kilogram) or control (dimethyl sulfoxide, 10%) products were injected intramyocardially into the RV under direct visualization. The cohorts were monitored for 3 months after product delivery with assessments of cardiac performance, rhythm, and serial cardiac biochemical markers, followed by terminal necropsy. No mortalities were associated with intramyocardial delivery of UCB-MNCs or placebo. Two animals from the placebo group developed local skin infection after surgery that responded to antibiotic treatment. Electrophysiological assessments revealed no arrhythmias in either group throughout the 3-month study. Two animals in the cell-therapy group had transient, subclinical dysrhythmia in the perioperative period, likely because of an exaggerated response to anesthesia. Overall, this study demonstrated that autologous UCB-MNCs can be safely collected and surgically delivered in a pediatric setting. The safety profile establishes the foundation for cell-based therapy directed at the RV of juvenile hearts and aims to accelerate cell-based therapies toward clinical trials for CHD. ©AlphaMed Press.

Entities:  

Keywords:  Autologous umbilical cord blood; Congenital heart disease; Intramyocardial delivery; Porcine; Right ventricle; Safety

Mesh:

Year:  2015        PMID: 25561683      PMCID: PMC4303361          DOI: 10.5966/sctm.2014-0195

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  33 in total

1.  Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery.

Authors:  Qiang Zhao; Yongxin Sun; Limin Xia; Anqing Chen; Zhe Wang
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

2.  Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone.

Authors:  Keng-Leong Ang; Derek Chin; Francisco Leyva; Paul Foley; Chandrashekhar Kubal; Shajil Chalil; Lakshmi Srinivasan; Lizelle Bernhardt; Suzanne Stevens; Lincoln T Shenje; Manuel Galiñanes
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-08-19

3.  Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study.

Authors:  Evgeny Pokushalov; Alexander Romanov; Alexander Chernyavsky; Petr Larionov; Igor Terekhov; Sergey Artyomenko; Olga Poveshenko; Elena Kliver; Natalya Shirokova; Alexandr Karaskov; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2009-09-24       Impact factor: 4.132

4.  Human umbilical cord blood cells in infarcted rats.

Authors:  V Pinho-Ribeiro; A C V Maia; J P S Werneck-de-Castro; P F Oliveira; R C S Goldenberg; A C Campos de Carvalho
Journal:  Braz J Med Biol Res       Date:  2010-03       Impact factor: 2.590

Review 5.  Direct autologous bone marrow-derived stem cell transplantation for ischemic heart disease: a meta-analysis.

Authors:  Yanting Wen; Li Meng; Jun Xie; Jian Ouyang
Journal:  Expert Opin Biol Ther       Date:  2011-03-10       Impact factor: 4.388

6.  Human cord blood cells and myocardial infarction: effect of dose and route of administration on infarct size.

Authors:  Robert J Henning; Jose D Burgos; Mark Vasko; Felipe Alvarado; Cyndy D Sanberg; Paul R Sanberg; Michael B Morgan
Journal:  Cell Transplant       Date:  2007       Impact factor: 4.064

7.  Optimal length of time of cryopreserved umbilical cord blood infusion after thawing.

Authors:  Lu Huang; Gui-Qi Song; Yun Wu; Jian Wang; Zi-Min Sun
Journal:  Hematology       Date:  2013-11-25       Impact factor: 2.269

8.  A regenerative strategy for heart failure in hypoplastic left heart syndrome: intracoronary administration of autologous bone marrow-derived progenitor cells.

Authors:  Stefan Rupp; Andreas M Zeiher; Stefanie Dimmeler; Torsten Tonn; Juergen Bauer; Christian Jux; Hakan Akintuerk; Dietmar Schranz
Journal:  J Heart Lung Transplant       Date:  2009-12-31       Impact factor: 10.247

9.  Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy.

Authors:  Stefan Rupp; Jürgen Bauer; Torsten Tonn; Volker Schächinger; Stefanie Dimmeler; Andreas M Zeiher; Dietmar Schranz
Journal:  Pediatr Transplant       Date:  2009-11-26

10.  Human cord blood stem cells enhance neonatal right ventricular function in an ovine model of right ventricular training.

Authors:  Ben Davies; Ngaire J Elwood; Shan Li; Fiona Cullinane; Glenn A Edwards; Donald F Newgreen; Christian P Brizard
Journal:  Ann Thorac Surg       Date:  2010-02       Impact factor: 4.330

View more
  10 in total

Review 1.  Stem cell therapy for CHD: towards translation.

Authors:  Brody Wehman; Osama T Siddiqui; Rachana Mishra; Sudhish Sharma; Sunjay Kaushal
Journal:  Cardiol Young       Date:  2015-08       Impact factor: 1.093

2.  Characterization and angiogenic potential of human neonatal and infant thymus mesenchymal stromal cells.

Authors:  Shuyun Wang; Lakshmi Mundada; Sean Johnson; Joshua Wong; Russell Witt; Richard G Ohye; Ming-Sing Si
Journal:  Stem Cells Transl Med       Date:  2015-02-23       Impact factor: 6.940

Review 3.  The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy.

Authors:  Jianxiang Zhong; Shengbing Wang; Wei-Bin Shen; Sunjay Kaushal; Peixin Yang
Journal:  Pediatr Res       Date:  2017-11-15       Impact factor: 3.756

Review 4.  Stem cell therapy and tissue engineering for correction of congenital heart disease.

Authors:  Elisa Avolio; Massimo Caputo; Paolo Madeddu
Journal:  Front Cell Dev Biol       Date:  2015-06-30

5.  Age-Dependent Effect of Pediatric Cardiac Progenitor Cells After Juvenile Heart Failure.

Authors:  Udit Agarwal; Amanda W Smith; Kristin M French; Archana V Boopathy; Alex George; David Trac; Milton E Brown; Ming Shen; Rong Jiang; Janet D Fernandez; Brian E Kogon; Kirk R Kanter; Baahaldin Alsoufi; Mary B Wagner; Manu O Platt; Michael E Davis
Journal:  Stem Cells Transl Med       Date:  2016-05-05       Impact factor: 6.940

Review 6.  Stem Cell Therapy and Congenital Heart Disease.

Authors:  Timothy J Nelson; Susana Cantero Peral
Journal:  J Cardiovasc Dev Dis       Date:  2016-07-05

7.  Banking of AT-MSC and its Influence on Their Application to Clinical Procedures.

Authors:  Ekaterina Semenova; Mariusz P Grudniak; Katarzyna Bocian; Magdalena Chroscinska-Krawczyk; Marzena Trochonowicz; Igor M Stepaniec; Magdalena Murzyn; Ilona Szablowska-Gadomska; Dariusz Boruczkowski; Tomasz Oldak; Eugeniusz K Machaj
Journal:  Front Bioeng Biotechnol       Date:  2021-11-30

8.  Autologous Umbilical Cord Blood-Derived Mononuclear Cell Therapy Promotes Cardiac Proliferation and Adaptation in a Porcine Model of Right Ventricle Pressure Overload.

Authors:  Saji Oommen; Susana Cantero Peral; Muhammad Y Qureshi; Kimberly A Holst; Harold M Burkhart; Matthew A Hathcock; Walter K Kremers; Emma B Brandt; Brandon T Larsen; Joseph A Dearani; Brooks S Edwards; Joseph J Maleszewski; Timothy J Nelson
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.139

9.  Mesenchymal Stem/Stromal Cells from Discarded Neonatal Sternal Tissue: In Vitro Characterization and Angiogenic Properties.

Authors:  Shuyun Wang; Lakshmi Mundada; Eric Colomb; Richard G Ohye; Ming-Sing Si
Journal:  Stem Cells Int       Date:  2015-12-06       Impact factor: 5.443

10.  Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?

Authors:  Fanny Loisel; Bastien Provost; François Haddad; Julien Guihaire; Myriam Amsallem; Bojan Vrtovec; Elie Fadel; Georges Uzan; Olaf Mercier
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.